The Life Sciences team advised Kymera Therapeutics Inc. on its $102 million Series C financing.
Kymera is a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients. Kymera’s Pegasus targeted protein degradation platform harnesses the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics.
The round was led by Biotechnology Value Fund (BVF) and Redmile Group with participation from Wellington Management Company, Bain Capital Life Sciences, funds managed by Janus Henderson Investors and BlackRock, Rock Springs Capital and a large US-based, healthcare-focused fund. Existing investors also participated in the round. Kymera also received a strategic investment from The Leukemia & Lymphoma Society‘s Therapy Acceleration Program® (LLS TAP) directed toward advancing the company’s work to treat blood-based cancers.
The Goodwin team was led by William Collins and included Gabriela Morales-Rivera, Kim Maruncic, Katie Hand and Matt Rosencranz (corporate), Dan Karelitz (tax), with invaluable assistance from Katie Maxwell and Kathy Georgian.